← All trials
NCT05215574
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2022
- Primary completion
- Feb 29, 2024
- Completion date
- Dec 31, 2024
- First posted
- Jan 31, 2022
- Last posted
- Dec 26, 2022
- Enrollment
- 79
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- NGM Biopharmaceuticals, IncLead sponsor
- MerckCollaborator
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Transitional Cell
- Uterine Cervical Neoplasms
- Esophageal Neoplasms
- Melanoma
- Mesothelioma
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Prostatic Neoplasms
- Stomach Neoplasms
- Colorectal Neoplasms
- Cholangiocarcinoma
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.